Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM5A | P29375 | 2/20 | 0.61 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.61 |
| ▸ | ASPH | Q12797 | 2/20 | 0.61 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.61 |
| ▸ | KDM4A | O75164 | 2/20 | 0.61 |
| ▸ | KDM5C | P41229 | 2/20 | 0.61 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.61 |
| ▸ | KDM6B | O15054 | 1/20 | 0.61 |
| ▸ | TET3 | O43151 | 1/20 | 0.61 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.61 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.61 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.61 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.61 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.61 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.61 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387501 | 0.81 | ADORA3 (0.45) | KDM4EALDH1A1KDM5AKDM3AASPH | |
| SCHEMBL2643035 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1KDM5AKDM3AASPH | |
| SCHEMBL30800092 | 0.79 | KMO (0.71) | KDM4EALDH1A1KDM5AKDM3AASPH | |
| SCHEMBL7513922 | 0.79 | KMO (0.71) | KDM4EALDH1A1KDM5AKDM3AASPH | |
| SCHEMBL2097713 | 0.77 | KDM4E (0.59) | KDM4EALDH1A1KDM5AKDM3AASPH | |
| SCHEMBL2644050 | 0.76 | KDR (0.46) | KDM4EALDH1A1MAPTKDM4CLMNA | |
| SCHEMBL2643031 | 0.76 | ALDH1A1 (0.40) | KDM4EALDH1A1KDM5AKDM3AASPH | |
| SCHEMBL131789 | 0.76 | ALDH1A1 (0.50) | KDM4EALDH1A1KDM3AKDM5CKDM6B | |
| SCHEMBL4947094 | 0.76 | ALDH1A1 (0.43) | KDM4EALDH1A1KDM5AKDM3AASPH | |
| SCHEMBL65841 | 0.76 | KDM4E (0.63) | KDM4EALDH1A1KDM5AKDM3AASPH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | claimed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | claimed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | claimed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | claimed |
| EP-3112352-A1 | OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-01-04 | — | — | EP | claimed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | claimed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | claimed |
| EP-1725537-B1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-13 | — | — | EP | claimed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | claimed |
| CN-1950342-A | Novel compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2007-04-18 | — | — | CN | claimed |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| EP-3112352-B1 | OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-21 | — | — | EP | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| CN-104955332-B | The method of preventing and treating arthropod insect | 住友化学株式会社 | 2017-03-29 | — | — | CN | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| CN-1263746-C | Pyridazinone derivatives | NIHON NOHYAKU CO LTD (JP) | 2006-07-12 | — | — | CN | disclosed |
| US-6469003-B1 | COMPOUNDS HAVING CELL ADHESION INHIBITING ACTIVITY | NIHON NOHYAKU CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| CN-1323297-A | Pyridazinone derivatives | NIHON NOHYAKU CO LTD (JP) | 2001-11-21 | — | — | CN | disclosed |
| EP-1130015-A1 | PYRIDAZINONE DERIVATIVES | Nihon Nohyaku Co., Ltd. (JP) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | KDM4E 3213/4885ALDH1A1 528/4885KDM5A 3567/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | KDM4E 3224/4885ALDH1A1 517/4885KDM5A 3572/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | KDM4E 3224/4885ALDH1A1 517/4885KDM5A 3572/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | KDM4E 1902/4885ALDH1A1 580/4885KDM5A 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.